Jul. 13 at 12:00 PM
$LEGN
- Resuming coverage at "Neutral" is a strategic baseline for the newly assigned analyst, Jessica Fye. It establishes their model publicly without taking an aggressive stance, allowing them to keep their powder dry until the next major clinical catalyst forces an upgrade.
- JPMorgan's coverage note explicitly states that Carvykti's current commercial performance justifies a baseline valuation in the "high
$20S to
$30 per share range". The remaining premium in their
$35 target accounts for the potential of their early-stage pipeline assets.
- The Neutral rating acts as a "show me" hurdle. JPMorgan noted that there is no near-term catalyst to lift competitive overhangs. They want concrete proof that Legend's in vivo CAR-T platform can successfully scale into a second pillar of revenue to fend off emerging competitive threats in the multiple myeloma space (like anito-cel and the Tec-Dara combination) before officially recommending the stock as a "Buy".
